Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

Researchers develop a new method to remove old cells from tissues to slow down aging

No one knows why some people age worse than others and develop diseases -such as Alzheimer's, fibrosis, type 2 diabetes or some types of cancer- associated with this ageing process.

20 Oct 2021

New research on phagocytosis and SARS-CoV-2's spike protein

A new study showed that convalescent patient plasma and monoclonal anti-spike antibodies were able to induce phagocytosis at high antibody concentrations.

20 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

New oligomer shows promising anti-SARS-CoV-2 properties

Scientists from the University Of New Mexico have recently identified a new cationic oligomer that may help inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Oct 2021

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

20 Oct 2021

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

In a recent study published in the journal PLOS Pathogens, scientists showed that nasal administration of a single-domain antibody (VHH), named K-874A, brought about inhibition of SARS-CoV-2 titers in infected lungs of Syrian hamsters.

19 Oct 2021

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

A group of researchers from the United States discovered that the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce the formation of highly inflammatory blood clots amenable to neutralization by a fibrin-targeting monoclonal antibody – opening the door for a completely new strategy to reduce thrombotic inflammation in coronavirus disease 2019 (COVID-19).

17 Oct 2021

New protocol reduces hospitalizations, deaths of liver and kidney transplant patients with COVID-19

Liver and kidney transplant recipients have a higher risk of severe COVID-19 and/or death should they become infected because the medication they take to ensure a successful transplant suppresses their immune systems.

15 Oct 2021

Covid testing, turnaround times are still uneven this far into pandemic

In one recent week, a New Yorker got a free covid-19 test in a jiffy, with results the next day, while a Coloradan had to shell out $50 for a test two cities from her hometown after a frantic round of pharmacy-hopping.

14 Oct 2021

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Adapting biological research and development to COVID-19

In this interview, News-Medical talks to Dr Yuning Chen, about the work he does with Sino Biological and how they have adapted their research & development to the COVID-19 pandemic.

From Sino Biological Inc. 8 Oct 2021

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

7 Oct 2021

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.

6 Oct 2021

SARS-CoV-2 emerging variants display enhanced syncytia formation

Researchers compared the replication and syncytia forming potential of Alpha, Beta, and D614G strains in human cell lines and primary airway cells.

6 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Monoclonal Antibody News and Research

Further Reading

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Researchers develop a new method to remove old cells from tissues to slow down aging

New research on phagocytosis and SARS-CoV-2's spike protein

The neutralization potential of nanobodies against SARS-CoV-2

New oligomer shows promising anti-SARS-CoV-2 properties

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

Nasal delivery of single-domain antibodies improves SARS-CoV-2 symptoms in animal model

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

New protocol reduces hospitalizations, deaths of liver and kidney transplant patients with COVID-19

Covid testing, turnaround times are still uneven this far into pandemic

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

Adapting biological research and development to COVID-19

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

SARS-CoV-2 emerging variants display enhanced syncytia formation

Using a new public antibody to understand SARS-CoV-2 neutralization

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Novel Assay Platform for 3D Microfluidic Cancer Research

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®